| Dr Paul R Tarnasky, MD | |
|
221 W Colorado Blvd, Pav Ll Suite #630, Dallas, TX 75208-2363 | |
| (214) 941-6891 | |
| (214) 943-5871 |
| Full Name | Dr Paul R Tarnasky |
|---|---|
| Gender | Male |
| Speciality | Gastroenterology |
| Experience | 35 Years |
| Location | 221 W Colorado Blvd, Dallas, Texas |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1083674832 | NPI | - | NPPES |
| 200478210 A | Medicaid | OK | |
| 044507401 | Medicaid | TX | |
| 85Y154 | Other | TX | BCBSTX |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RG0100X | Internal Medicine - Gastroenterology | K2602 (Texas) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Methodist Dallas Medical Center | Dallas, TX | Hospital |
| Methodist Charlton Medical Center | Dallas, TX | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Physician Associates Of Southwest Dallas | 3274519293 | 30 |
| Texas Digestive Disease Consultants Pllc | 3375531379 | 544 |
News Archive
The Food and Drug Administration (FDA) today announced the formation of a multidisciplinary FDA task force on human cell and tissue safety.
Today on World Asthma Day 2011, despite decades of progress on the management and control of asthma – more research, better understanding and powerful treatments – millions of people with severe asthma are still living with serious, frequent, life-threatening symptoms.
Scientists generate a VLP type NP platform made of recombinant viral antigens conjugated with TMV virions.
ProtoKinetix, announces today that it has completed the sale of (AAGP) as a vital tool to protect delicate cells in the process of utilizing stem cells, to treat disease and injury. This development will enable the Company to ramp up sales of the unique AAGP family of molecules to the medical research community.
Abraxis BioScience, Inc. today announced that its randomized registrational Phase 3 clinical trial comparing ABRAXANE® (protein-bound paclitaxel) with Taxol® (paclitaxel) injection, both in combination with carboplatin, met the study's primary endpoint by demonstrating that ABRAXANE showed a significant improvement in overall response rate as compared to Taxol, in the first-line treatment of patients with advanced non-small cell lung cancer (NSCLC), as assessed by independent radiologist review.
› Verified 1 days ago
| Entity Name | Digestive Health Associates Of Texas Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1831158310 PECOS PAC ID: 2769372150 Enrollment ID: O20040318001014 |
News Archive
The Food and Drug Administration (FDA) today announced the formation of a multidisciplinary FDA task force on human cell and tissue safety.
Today on World Asthma Day 2011, despite decades of progress on the management and control of asthma – more research, better understanding and powerful treatments – millions of people with severe asthma are still living with serious, frequent, life-threatening symptoms.
Scientists generate a VLP type NP platform made of recombinant viral antigens conjugated with TMV virions.
ProtoKinetix, announces today that it has completed the sale of (AAGP) as a vital tool to protect delicate cells in the process of utilizing stem cells, to treat disease and injury. This development will enable the Company to ramp up sales of the unique AAGP family of molecules to the medical research community.
Abraxis BioScience, Inc. today announced that its randomized registrational Phase 3 clinical trial comparing ABRAXANE® (protein-bound paclitaxel) with Taxol® (paclitaxel) injection, both in combination with carboplatin, met the study's primary endpoint by demonstrating that ABRAXANE showed a significant improvement in overall response rate as compared to Taxol, in the first-line treatment of patients with advanced non-small cell lung cancer (NSCLC), as assessed by independent radiologist review.
› Verified 1 days ago
| Entity Name | Texas Digestive Disease Consultants Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1053397331 PECOS PAC ID: 3375531379 Enrollment ID: O20040505001844 |
News Archive
The Food and Drug Administration (FDA) today announced the formation of a multidisciplinary FDA task force on human cell and tissue safety.
Today on World Asthma Day 2011, despite decades of progress on the management and control of asthma – more research, better understanding and powerful treatments – millions of people with severe asthma are still living with serious, frequent, life-threatening symptoms.
Scientists generate a VLP type NP platform made of recombinant viral antigens conjugated with TMV virions.
ProtoKinetix, announces today that it has completed the sale of (AAGP) as a vital tool to protect delicate cells in the process of utilizing stem cells, to treat disease and injury. This development will enable the Company to ramp up sales of the unique AAGP family of molecules to the medical research community.
Abraxis BioScience, Inc. today announced that its randomized registrational Phase 3 clinical trial comparing ABRAXANE® (protein-bound paclitaxel) with Taxol® (paclitaxel) injection, both in combination with carboplatin, met the study's primary endpoint by demonstrating that ABRAXANE showed a significant improvement in overall response rate as compared to Taxol, in the first-line treatment of patients with advanced non-small cell lung cancer (NSCLC), as assessed by independent radiologist review.
› Verified 1 days ago
| Entity Name | Physician Associates Of Southwest Dallas |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1801845425 PECOS PAC ID: 3274519293 Enrollment ID: O20040629000498 |
News Archive
The Food and Drug Administration (FDA) today announced the formation of a multidisciplinary FDA task force on human cell and tissue safety.
Today on World Asthma Day 2011, despite decades of progress on the management and control of asthma – more research, better understanding and powerful treatments – millions of people with severe asthma are still living with serious, frequent, life-threatening symptoms.
Scientists generate a VLP type NP platform made of recombinant viral antigens conjugated with TMV virions.
ProtoKinetix, announces today that it has completed the sale of (AAGP) as a vital tool to protect delicate cells in the process of utilizing stem cells, to treat disease and injury. This development will enable the Company to ramp up sales of the unique AAGP family of molecules to the medical research community.
Abraxis BioScience, Inc. today announced that its randomized registrational Phase 3 clinical trial comparing ABRAXANE® (protein-bound paclitaxel) with Taxol® (paclitaxel) injection, both in combination with carboplatin, met the study's primary endpoint by demonstrating that ABRAXANE showed a significant improvement in overall response rate as compared to Taxol, in the first-line treatment of patients with advanced non-small cell lung cancer (NSCLC), as assessed by independent radiologist review.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Paul R Tarnasky, MD 7610 N Stemmons Fwy Ste 600, Dallas, TX 75247-4228 Ph: (214) 689-5960 | Dr Paul R Tarnasky, MD 221 W Colorado Blvd, Pav Ll Suite #630, Dallas, TX 75208-2363 Ph: (214) 941-6891 |
News Archive
The Food and Drug Administration (FDA) today announced the formation of a multidisciplinary FDA task force on human cell and tissue safety.
Today on World Asthma Day 2011, despite decades of progress on the management and control of asthma – more research, better understanding and powerful treatments – millions of people with severe asthma are still living with serious, frequent, life-threatening symptoms.
Scientists generate a VLP type NP platform made of recombinant viral antigens conjugated with TMV virions.
ProtoKinetix, announces today that it has completed the sale of (AAGP) as a vital tool to protect delicate cells in the process of utilizing stem cells, to treat disease and injury. This development will enable the Company to ramp up sales of the unique AAGP family of molecules to the medical research community.
Abraxis BioScience, Inc. today announced that its randomized registrational Phase 3 clinical trial comparing ABRAXANE® (protein-bound paclitaxel) with Taxol® (paclitaxel) injection, both in combination with carboplatin, met the study's primary endpoint by demonstrating that ABRAXANE showed a significant improvement in overall response rate as compared to Taxol, in the first-line treatment of patients with advanced non-small cell lung cancer (NSCLC), as assessed by independent radiologist review.
› Verified 1 days ago
Uma B.r.k Pakkivenkata, M.D. Gastroenterology Medicare: Accepting Medicare Assignments Practice Location: 9900 N Central Expy Ste 215, Dallas, TX 75231 Phone: 214-396-4950 Fax: 877-423-5360 | |
Dr. Ariel Marcelo Modrykamien, M.D. Gastroenterology Medicare: Accepting Medicare Assignments Practice Location: 3600 Gaston Ave, Wadley Tower, Suite 960, Dallas, TX 75246 Phone: 402-972-6078 | |
Benjamin Seth Martinez, MD Gastroenterology Medicare: Not Enrolled in Medicare Practice Location: 5323 Harry Hines Blvd, Dallas, TX 75390 Phone: 214-648-3111 Fax: 214-648-5461 | |
Vijaya Mummadi, M.D. Gastroenterology Medicare: Accepting Medicare Assignments Practice Location: 9900 N Central Expy Ste 225, Dallas, TX 75231 Phone: 469-646-8880 Fax: 469-646-8884 | |
Dr. Ting-yi Chen, M.D. Gastroenterology Medicare: Not Enrolled in Medicare Practice Location: 5323 Harry Hines Blvd, Dallas, TX 75390 Phone: 214-645-2800 Fax: 214-645-2808 | |
William Cook Langmade, MD Gastroenterology Medicare: Medicare Enrolled Practice Location: 1441 N Beckley Ave, Dallas, TX 75203 Phone: 214-947-2306 | |
Dr. Janame J Kottey, MBBS Gastroenterology Medicare: Accepting Medicare Assignments Practice Location: 13154 Coit Rd Ste 100, Dallas, TX 75240 Phone: 214-358-2300 Fax: 214-579-6989 |